title: [Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
abstract: The effects of lansoprazole given intravenously on gastric mucosal lesions, gastric bleeding and acid secretion were investigated in rats in comparison with those of omeprazole, famotidine and ranitidine. Lansoprazole inhibited the formation of gastric mucosal lesions in rats induced by water-immersion stress or aspirin with ID50 values of 0.26 and 0.99 mg/kg, respectively, and also inhibited gastric bleeding induced by hemorrhagic shock or water-immersion stress with ID50 values of 0.46 and 1.22 mg/kg, respectively. Lansoprazole was more potent than omeprazole, famotidine and ranitidine in inhibiting gastric mucosal lesions and hemorrhagic shock- or stress-induced bleeding. Famotidine and ranitidine showed negligible inhibition of water-immersion stress-induced gastric bleeding. Lansoprazole strongly inhibited water-immersion stress-stimulated acid secretion in rats, whereas famotidine and ranitidine did not show a potent inhibitory effect. These results indicate that lansoprazole exerts prominent inhibitory actions against the formation of gastric mucosal lesions and gastric bleeding by inhibiting acid secretion, and they show that it is superior to histamine H2-receptor antagonists in inhibiting stress-induced gastric bleeding.
authors.affiliation: Pharmaceutical Research Laboratories III, Takeda Chemical Industries, Ltd., Osaka, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Inatomi
authors.forename: I
authors.initials: I
authors.lastname: Murakami
authors.forename: S
authors.initials: S
authors.lastname: Asano
authors.forename: I
authors.initials: I
authors.lastname: Inada
authors.forename: H
authors.initials: H
authors.lastname: Satoh
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000208:Acute Disease; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D015738:Famotidine / Q000627:therapeutic use; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects*; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D007275:Injections, Intravenous; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013312:Stress, Physiological
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D064747:Lansoprazole; D015738:Famotidine; D011899:Ranitidine; D009853:Omeprazole